173 related articles for article (PubMed ID: 11155085)
1. The tumour vanishes.
Todd JF; Meeran K
Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
[No Abstract] [Full Text] [Related]
2. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
Imtiaz KE; Monteith P; Khaleeli A
Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
[TBL] [Abstract][Full Text] [Related]
3. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
4. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin Analogues in Neuroendocrine Tumors.
Kulke MH
J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
[No Abstract] [Full Text] [Related]
7. Recent advances in carcinoid pathogenesis, diagnosis and management.
Ganim RB; Norton JA
Surg Oncol; 2000 Dec; 9(4):173-9. PubMed ID: 11476988
[TBL] [Abstract][Full Text] [Related]
8. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
9. Carcinoid tumor regression with high-dose octreotide acetate: a patient report.
Lokich J
Am J Clin Oncol; 1998 Jun; 21(3):246-7. PubMed ID: 9626790
[TBL] [Abstract][Full Text] [Related]
10. Carcinoid tumour management in haemodialysis: a case report.
Burke MT; Gray NA
Nephrology (Carlton); 2012 Feb; 17(2):198. PubMed ID: 22257155
[No Abstract] [Full Text] [Related]
11. Octreotide LAR in carcinoid: how to dose?
Yao JC; Kvols LK
Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
[No Abstract] [Full Text] [Related]
12. [Isotopic scan with somatostatin receptors in a case of recurrent carcinoid tumor. Relevance of tomographic detection].
Bernà Roqueta L; Martín Marimón JC; Martín Martínez J
Rev Esp Med Nucl; 2002 Apr; 21(2):123-4. PubMed ID: 11879622
[No Abstract] [Full Text] [Related]
13. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal carcinoid tumor: successful therapy for a tumor in a unique location.
Warman M; Halperin D; Poria Y; Huszar M; Idelevich E
Otolaryngol Head Neck Surg; 2009 Mar; 140(3):437-8. PubMed ID: 19248962
[No Abstract] [Full Text] [Related]
15. [Current treatment of carcinoid tumor].
Elizalde I; Borda F
Gastroenterol Hepatol; 2002 Oct; 25(8):508-13. PubMed ID: 12361534
[No Abstract] [Full Text] [Related]
16. Metastatic carcinoid tumour of the heart.
Debouverie O; Vaquette B; Hervochon JM
Arch Cardiovasc Dis; 2010; 103(8-9):491-2. PubMed ID: 21074130
[No Abstract] [Full Text] [Related]
17. Carcinoid crisis induced by repeated abdominal examination.
Morrisroe K; Sim IW; McLachlan K; Inder WJ
Intern Med J; 2012 Mar; 42(3):342-4. PubMed ID: 22432991
[No Abstract] [Full Text] [Related]
18. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
[No Abstract] [Full Text] [Related]
19. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
20. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
